vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and OLYMPIC STEEL INC (ZEUS). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $490.7M, roughly 1.3× OLYMPIC STEEL INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 0.4%, a 34.0% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.4%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 0.1%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Olympic Steel, Inc. is a metals service center based in Cleveland, Ohio. The company processes and distributes carbon, coated and stainless flat-rolled sheet, coil and plate steel, aluminium alloy, tin plate, and metal-intensive branded products primarily in the United States. Metals processing and value added services include tempering, stretch leveling, cutting-to-length, slitting, edging, shearing, blanking, burning, forming, shot blasting, laser punching, plate rolling, fabricating, machi...
RPRX vs ZEUS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $490.7M |
| Net Profit | $214.2M | $2.2M |
| Gross Margin | — | — |
| Operating Margin | 62.4% | 1.5% |
| Net Margin | 34.4% | 0.4% |
| Revenue YoY | 4.8% | 4.4% |
| Net Profit YoY | 2.9% | -21.2% |
| EPS (diluted) | $0.49 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | — | ||
| Q3 25 | $609.3M | $490.7M | ||
| Q2 25 | $578.7M | $496.5M | ||
| Q1 25 | $568.2M | $492.9M | ||
| Q4 24 | $593.6M | $418.8M | ||
| Q3 24 | $564.7M | $470.0M | ||
| Q2 24 | $537.3M | $526.3M | ||
| Q1 24 | $568.0M | $526.6M |
| Q4 25 | $214.2M | — | ||
| Q3 25 | $288.2M | $2.2M | ||
| Q2 25 | $30.2M | $5.2M | ||
| Q1 25 | $238.3M | $2.5M | ||
| Q4 24 | $208.2M | $3.9M | ||
| Q3 24 | $544.0M | $2.7M | ||
| Q2 24 | $102.0M | $7.7M | ||
| Q1 24 | $4.8M | $8.7M |
| Q4 25 | 62.4% | — | ||
| Q3 25 | 70.1% | 1.5% | ||
| Q2 25 | 36.3% | 2.3% | ||
| Q1 25 | 94.0% | 1.6% | ||
| Q4 24 | 60.9% | 2.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | 50.2% | 2.9% | ||
| Q1 24 | -13.0% | 3.0% |
| Q4 25 | 34.4% | — | ||
| Q3 25 | 47.3% | 0.4% | ||
| Q2 25 | 5.2% | 1.1% | ||
| Q1 25 | 41.9% | 0.5% | ||
| Q4 24 | 35.1% | 0.9% | ||
| Q3 24 | 96.3% | 0.6% | ||
| Q2 24 | 19.0% | 1.5% | ||
| Q1 24 | 0.8% | 1.7% |
| Q4 25 | $0.49 | — | ||
| Q3 25 | $0.67 | $0.18 | ||
| Q2 25 | $0.07 | $0.45 | ||
| Q1 25 | $0.55 | $0.21 | ||
| Q4 24 | $0.46 | $0.33 | ||
| Q3 24 | $1.21 | $0.23 | ||
| Q2 24 | $0.23 | $0.66 | ||
| Q1 24 | $0.01 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $7.5M |
| Total DebtLower is stronger | $9.0B | $240.9M |
| Stockholders' EquityBook value | $9.7B | $579.1M |
| Total Assets | $19.6B | $1.1B |
| Debt / EquityLower = less leverage | 0.92× | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | — | ||
| Q3 25 | $938.9M | $7.5M | ||
| Q2 25 | $631.9M | $14.8M | ||
| Q1 25 | $1.1B | $13.3M | ||
| Q4 24 | $929.0M | $11.9M | ||
| Q3 24 | $950.1M | $11.1M | ||
| Q2 24 | $1.8B | $9.4M | ||
| Q1 24 | $843.0M | $10.3M |
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | $240.9M | ||
| Q2 25 | $8.0B | $233.2M | ||
| Q1 25 | $7.6B | $235.4M | ||
| Q4 24 | $7.6B | $272.5M | ||
| Q3 24 | $7.6B | $197.3M | ||
| Q2 24 | $7.6B | $209.2M | ||
| Q1 24 | $6.1B | $196.8M |
| Q4 25 | $9.7B | — | ||
| Q3 25 | $9.6B | $579.1M | ||
| Q2 25 | $9.5B | $578.2M | ||
| Q1 25 | $9.8B | $574.2M | ||
| Q4 24 | $10.3B | $573.9M | ||
| Q3 24 | $10.3B | $570.6M | ||
| Q2 24 | $9.8B | $569.5M | ||
| Q1 24 | $9.9B | $563.0M |
| Q4 25 | $19.6B | — | ||
| Q3 25 | $19.3B | $1.1B | ||
| Q2 25 | $18.3B | $1.1B | ||
| Q1 25 | $17.6B | $1.1B | ||
| Q4 24 | $18.2B | $1.0B | ||
| Q3 24 | $18.0B | $1.0B | ||
| Q2 24 | $17.7B | $1.0B | ||
| Q1 24 | $16.1B | $1.0B |
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | 0.42× | ||
| Q2 25 | 0.84× | 0.40× | ||
| Q1 25 | 0.78× | 0.41× | ||
| Q4 24 | 0.74× | 0.47× | ||
| Q3 24 | 0.74× | 0.35× | ||
| Q2 24 | 0.78× | 0.37× | ||
| Q1 24 | 0.62× | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $-5.4M |
| Free Cash FlowOCF − Capex | — | $-12.9M |
| FCF MarginFCF / Revenue | — | -2.6% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | 3.86× | -2.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | — | ||
| Q3 25 | $702.6M | $-5.4M | ||
| Q2 25 | $364.0M | $15.5M | ||
| Q1 25 | $596.1M | $49.4M | ||
| Q4 24 | $742.5M | $14.6M | ||
| Q3 24 | $703.6M | $24.6M | ||
| Q2 24 | $658.2M | $-2.9M | ||
| Q1 24 | $664.6M | $-2.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-12.9M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $7.4M | ||
| Q3 24 | — | $15.6M | ||
| Q2 24 | — | $-11.3M | ||
| Q1 24 | — | $-7.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | -2.6% | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | -2.2% | ||
| Q1 24 | — | -1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | -2.50× | ||
| Q2 25 | 12.06× | 2.96× | ||
| Q1 25 | 2.50× | 19.70× | ||
| Q4 24 | 3.57× | 3.75× | ||
| Q3 24 | 1.29× | 9.01× | ||
| Q2 24 | 6.45× | -0.38× | ||
| Q1 24 | 139.10× | -0.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
ZEUS
| Carbon Flat Products | $268.2M | 55% |
| Specialty Metals Flat Products | $140.9M | 29% |
| Tubular And Pipe Products | $81.6M | 17% |
